Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making

See, Kay Choong

doi:10.3390/vaccines11050908

Cited by 3 publications

(3 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Severe pneumococcal disease may be prevented by pneumococcal vaccines [12]. Guidelines currently recommend pneumococcal vaccination among patients at risk of severe disease, identifying age and comorbidity as the main risk factors [12]. For healthy people, the target population for pneumococcal vaccination under the Japanese national immunization program includes adults aged 65 years and older [13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Disseminated Penicillin-Resistant Streptococcus pneumoniae Infection: A Case Report

Kodama,

Momozane,

Takehara

et al. 2024

Cureus

View full text Add to dashboard Cite

An invasive pneumococcal disease involving sternoclavicular joint arthritis, lumbar spondylodiscitis, and muscular abscesses caused by penicillin-resistant Streptococcus pneumoniae has not been reported previously. We successfully treated a 57-year-old man with this condition using surgical drainage and debridement, and laminectomy/fenestration, in combination with the administration of two IV antimicrobial drugs based on blood culture results. Clinical resolution was obtained after decompression of the lumbar spine, with minimal restriction of the left lower limb. This treatment approach should be considered depending on the pathogen, underlying host factors, and the severity of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Disseminated Penicillin-Resistant Streptococcus pneumoniae Infection: A Case Report

Kodama,

Momozane,

Takehara

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Pneumococcal disease remains widespread, even with the availability of vaccines, and can be fatal, particularly in children and older adults. S. pneumoniae causes non-invasive illnesses, such as otitis media and sinusitis, and more serious conditions, such as bacterial pneumonia, bacteremia, and meningitis [1][2][3][4]. The prevalence of penicillin-and macrolide-resistant S. pneumoniae strains is increasing [5,6].…”

Section: Introductionmentioning

confidence: 99%

The Pneumococcal Protein SufC Binds to Host Plasminogen and Promotes Its Conversion into Plasmin

Yasui,

Hirayama,

Hiyoshi

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Streptococcus pneumoniae causes otitis media, sinusitis, and serious diseases such as pneumonia and bacteremia. However, the in vivo dynamics of S. pneumoniae infections and disease severity are not fully understood. In this study, we investigated pneumococcal proteins detected in the bronchoalveolar lavage fluid of an S. pneumoniae-infected mouse, which were assumed to be expressed during infection. Analysis of three proteins with unknown infection-related functions revealed that recombinant Fe-S cluster assembly ATP-binding protein (SufC) binds to the host plasminogen and promotes its conversion into plasmin. SufC was detected in the bacterial cell-surface protein fraction, but it had no extracellular secretory signal. This study suggests that S. pneumoniae releases SufC extracellularly through LytA-dependent autolysis, binding to the bacterial cell surface and host plasminogen and promoting its conversion into plasmin. The recruitment of plasmin by S. pneumoniae is considered useful for bacterial survival and spread, and SufC is suggested to facilitate this process.

show abstract

Evaluating immune responses to pneumococcal vaccines

Thong,

Pawankar,

Park

et al. 2023

Asia Pacific Allergy

View full text Add to dashboard Cite

Streptococcus pneumoniae (pneumococcus) is a significant cause of bacterial infections ranging from mild infections affecting the respiratory tract such as otitis media and sinusitis to severe diseases including bacteremia, pneumonia, and invasive pneumococcal disease (IPD) (eg, meningitis, septic arthritis, and endocarditis). Pneumococcal vaccines were first developed in the 1970s as capsular pneumococcal polysaccharide vaccines, which were T-cell independent and hence lacked immunologic memory. Subsequently in the year 2000, pneumococcal conjugate vaccines (PCV) conjugated to a protein to increase immunogenicity were developed and made commercially available. The increasing number of pneumococcal serotypes identified and the expanding pipeline of PCV vaccines with improved immunogenicity have significantly reduced the morbidity and mortality associated with IPD in high-risk patients. Pneumococcal vaccines also play an important role in the diagnosis and immunophenotyping of children and adults with inborn errors of immunity (IEI) given the increasing diversity/heterogeneity of IEI presenting with primary and/or specific antibody deficiency. Other than the quantitation of serotype levels in routine clinical care, other measurements of immune response including the functional activity of antibodies, antibody avidity, cell-mediated immunity, and immunological memory remain limited to clinical trials during vaccine development.

show abstract

Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making

Cited by 3 publications

References 91 publications

Disseminated Penicillin-Resistant Streptococcus pneumoniae Infection: A Case Report

Disseminated Penicillin-Resistant Streptococcus pneumoniae Infection: A Case Report

The Pneumococcal Protein SufC Binds to Host Plasminogen and Promotes Its Conversion into Plasmin

Evaluating immune responses to pneumococcal vaccines

Contact Info

Product

Resources

About